Bridgewater, New Jersey, October 11, 2012 – Aptalis Pharmaceutical Technologies, formerly
Eurand, focused on developing differentiated oral products utilizing its pharmaceutical
technologies, today announces its sponsorship of the American Association of Pharmaceutical
Scientists (AAPS) Research Achievement Awards in Pharmacokinetics, Pharmacodynamics
and Drug Metabolism and its participation in the 2012 AAPS Annual Meeting and Exposition
October 14 – 18, 2012 in Chicago, Illinois. The 2012 annual meeting and exposition is an
international forum for the exchange of knowledge among an expected 9,000 attendees,
including scientists working in drug design, discovery, development, delivery, packaging, scale-
up, clinical trials, and regulatory sciences.
AAPS Research Achievement Awards
The AAPS Research Achievement Awards are intended to recognize outstanding scientists who
have conducted fundamental research that has had significant impact in the fields of
Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM). Aptalis Pharmaceutical
Technologies is the sponsor of the 2012 awards being presented during AAPS’ annual meeting
and exposition October 14–18 in Chicago. PPDM is the section of the American Association of
Pharmaceutical Scientists that provides an opportunity for the presentation of new data and an
exchange of ideas by individuals actively engaged in the various facets of pharmacokinetics,
pharmacodynamics, drug metabolism, transport, biopharmaceutics, and related sciences.
Aptalis APPS Poster Presentation and Recruitment
Meeting participants are invited to visit the Aptalis Pharmaceutical Technologies’ poster
presentation: T2132, “Development of orally disintegrating tablets comprising controlled-
release multiparticulate beads.” P.J. Stevens, G. Venkatesh, J. Lai, October 16, 2012, Hall
F, McCormick Place 9:30 a.m. to 12:30 p.m. and to visit the Aptalis Career Center Booth # CC1.
About Aptalis Pharmaceutical Technologies
Aptalis Pharmaceutical Technologies, formerly known as Eurand Pharmaceutical Technologies,
offers a broad portfolio of oral drug delivery technology platforms: Customized Drug Release,
Bioavailability Enhancement, and Taste Masking for ODT’s (orally disintegrating tablets) and
other dosage forms. Together, these technology platforms combined with licensing,
manufacturing, and R&D capabilities enable Aptalis Pharmaceutical Technologies to produce
customized drug formulation solutions for partners across a range of dosage forms and
therapies with high patient acceptability. Aptalis Pharmaceutical Technologies develops and
manufactures products for its partners, as well as supports the drug development process for
the Aptalis Pharma pipeline and portfolio of products. For more information about Aptalis
Pharmaceutical Technologies, visit www.AptalisPharmaTech.com
About Aptalis
Aptalis Pharma Inc. is a privately held, leading specialty pharmaceutical company providing
innovative, effective therapies for unmet medical needs including cystic fibrosis and
gastrointestinal disorders. Aptalis, formed from the recent combination of Axcan Pharma and
Eurand, has manufacturing and commercial operations in the United States, the European
Union and Canada, and its products include ZENPEP®, CANASA®, CARAFATE®, PYLERA®,
LACTEOL®, DELURSAN®, PANZYTRAT® and SALOFALK®. Aptalis also formulates and
clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and
others using its proprietary technology platforms including bioavailability enhancement of poorly
soluble drugs, custom release profiles, and taste-masking/orally disintegrating tablet (ODT)
formulations. For more information, visit www.aptalispharma.com.
Media Contact:
Erin O’Brien, Director of Marketing
Aptalis Pharmaceutical Technologies
908-927-9600, Ext. 4084
eobrien@aptalispharma.com